Topic Listing for Biogen Idec

Accounting Share-based Compensation Acorda
Acquired In-process Research Development Acquired In-process Research Development Iprd
Acquisition Syntonix Pharmaceuticals Inc Address Including Zip Code Telephone Number Area Registrants
Address Proposals Adentri
Adopted Several Anti-takeover Measures Well Other Protect Certain Adoption Fasb Interpretation
Adverse Safety Events Negatively Affect Assets Product Sales Affirm Study
Alnylam Amevive
Amortization Acquired Intangible Assets Amortization Intangible Assets
Amortization Stock Based Compensation Anti-cd23 Antibody Lumiliximab
Anti-cd23 Mab Lumiliximab Anti-cd80 Antibody
Anti-cd80 Antibody Galiximab Anti-cd80 Mab Galiximab
Area Code Registrants Principal Executive Offices Assets Held Sale
Assumptions Attendance Annual Meetings
Audit Committee Financial Experts Audit Other Fees
Autoimmune Inflammatory Diseases Available Information
Avonex Avonex Interferon Beta-1a
Avonex Tysabri Awards Equity Plans
Base Salary Basis Presentation
Beneficial Ownership Reporting Compliance Benefits
Bg-12 Bg-12 Panaclar
Biogen Idec Inc Biogen Idec Inc Form 10-q Quarterly Report Period
Biogen-dompe Biovitrum
Board Directors Shareholders Biogen Idec Inc Borrowings
Business Development Business Highlights
Business Involves Environmental Risks Business Involves Environmental Risks Include Cost Compliance Risk
Business Negatively Affected Result Actions Activist Shareholders Business Negatively Affected Result Threatened Proxy Fight Other
Business Overview Business Subject Extensive Governmental Regulation Oversight Changes Laws
Cambridge Center 02142 617 679-2000 Cambridge Massachusetts
Cambridge Massachusetts Surrounding Area Canada
Capitalization Inventory Costs Cardiokine
Cardiokine Biopharma Llc Cardiovascular
Cash Equivalents Certain Relationships Related Person Transactions
Certification Certification Chief Executive Officer Pursuant 302 Sarbanes-oxley Act
Certification Chief Financial Officer Pursuant 302 Sarbanes-oxley Act Certification Pursuant 906 Sarbanes-oxley Act 2002
Certification Pursuant 906 Sarbanes-oxley Act 2002 Subsections 1350 Change Accounting Principle Related Tax Effects Share-based Payment
Change Vote Changes Internal Control Over Financial Reporting
Changes Laws Affecting Healthcare Industry Adversely Affect Revenues Clinical Studies
Collaboration License Agreements Collaboration Profit Loss Sharing
Collaboration Profit Sharing Commitments
Committees Compensation Management Development Committee Report
Competition Competition Industry Markets Products Intense
Composition Committees Information Meetings Comprehensive Income
Comprehensive Income Loss Comprehensive Strategic Plan
Concentration Credit Risks Conforma
Consent Independent Registered Public Accounting Firm Consolidated Financial Statements
Consolidated Financial Statements Statement Schedule Construction Commitments
Contingencies Litigation Contingency
Contractual Adjustments Contractual Obligations Off-balance Sheet Arrangements
Controls Procedures Conversion Senior Notes Due 2019
Corporate Governance Corporate Partner Revenues
Cost Product Revenues Cost Product Royalty Revenues
Cost Royalty Revenue Cost Royalty Revenues
Cost Sales Excluding Amortization Acquired Intangible Assets Cost Sales Excluding Amortization Intangible Assets
Costs Expenses Critical Accounting Estimates
Current Credit Financial Market Conditions Exacerbate Certain Risks Debt Maturity
Deferred Compensation Plan Deferred Tax Assets Liabilities
Depend Collaborators Product Royalty Revenue Clinical Development Future Depend Significant Extent Reimbursement Party Payors Reduction Negatively
Depend Significant Extent Reimbursement Party Payors Reduction Reduce Derivatives Hedging Activities
Developments Did Send Proxy Statement
Directions Boston Marriott Cambridge Hotel Director Compensation
Director Equity Outstanding 2006 Year-end Director Equity Outstanding 2007 Year-end
Director Independence Director Qualification Standards
Disclosure Controls Procedures Disclosure Controls Procedures Internal Control Over Financial Reporting
Disclosure Respect Equity Compensation Plans Discounts
Dividends Documents Incorporated Reference
Earnings Per Share Effective Tax Rate Fluctuate Incur Liabilities Authorities Excess
Effective Tax Rate Fluctuate Incur Obligations Jurisdictions Excess Elan
Election Directors Emerging Therapeutic Areas
Employee Savings Plan Employee Stock Purchase Plan
Employees Enact-1 Enact-2
Encore Study Equity Compensation Plan Information
Equity Compensation Plan Table Espp
Estimates Evaluating Investments Other-than-temporary Impairments
Exact Name Registrant Specified Charter Executive Compensation Philosophy Objectives
Executive Overview Executive Severance Policy
Executive Summary Exposed Risk Interest Rate Fluctuations
Facet Biotech Facet Biotech Formerly Pdl Biopharma Inc
Facility Impairments Gain Loss Disposition Net Facility Impairments Loss Sale
Fail Compete Effectively Business Market Position Suffer Fail Comply Extensive Legal Regulatory Requirements Affecting Healthcare
Fail Meet Stringent Requirements Governmental Regulation Manufacture Products Failure Comply Government Regulations Regarding Products Harm Business
Failure Prevail Litigation Satisfactorily Resolve Party Investigation Harm Fair Value Financial Instruments
Fair Value Measurements Fasb Interpretation
Fin Fin Assessment
Finance Audit Committee Finance Audit Committee Report
Financial Condition Financial Expert
Financial Highlights Financial Position Results Operations Cash Flows Affected Fluctuations
Financing Activities Find Voting Results Meeting
Form 10-k Form 10-q
Forward Contracts Forward Contracts Interest Rate Swaps
Forward-looking Information Fumaderm
Fumaderm Dimethylfumarate Monoethylfumarate Salts Fumapharm
Fumedica Fumedica Agreements
Future Transactions Harm Business Market Price Stock Gain Loss Settlement License Agreements Net
Gain Sale Property Gain Settlement License Agreements Net
Galiximab Anti-cd80 Antibody Genentech
General Goal-setting Performance Assessment Influence Compensation Decisions
Goodwill Growth Business Depends Ability Attract Retain Qualified Personnel
Hillerød Denmark Holders
Humanized Anti-cd20 Mab Ocrelizumab Impairment
Impairment Investments Impairment Long-lived Assets
Impairments Long-lived Assets In-process Research Development Iprd
Income Tax Expense Income Tax Provision
Income Taxes Incorporation Reference
Incur Liabilities Tax Authorities Excess Amounts Been Accrued Independent Registered Public Accounting Firm
Index Information Class Directors Terms Expire 2008
Information Directors Information Executive Officers
Information Nominating Processes Information Nominees Election Class Directors Terms Expire 2010
Intangible Assets Intangible Assets Excluding Goodwill
Intangible Assets Goodwill Intangibles Other Goodwill
Interest Expense Interest Income
Interest Rate Swaps Internal Control Over Financial Reporting
International Sales Operations Subject Risks Doing Business Abroad Introduction Corporate Governance
Inventory Inventory Write-offs
Investing Activities Investments
Investments Marketable Securities Significant Subject Interest Credit Risk Investments Marketable Securities Significant Subject Market Interest Credit
Irs Settlement Issuer Purchases Equity Securities
Late-stage Product Candidates Leases
Legal Matters Legislative Regulatory Changes Harm Business
Level Indebtedness Adversely Affect Business Limit Ability Plan Lixivaptan
Loans Receivable Long-lived Assets
Long-term Incentives Long-term Success Depends Successful Development Commercialization Other Product
Long-term Success Depends Successful Development Commercialization Other Products Lumiliximab Anti-cd23 Antibody
Managements Annual Report Internal Control Over Financial Reporting Manufacture Products Subject Government Regulation
Manufacturing Problems Result Inability Deliver Products Inventory Shortages Manufacturing Raw Materials
Manufacturing Selling Marketing Efforts Market Acceptance Successful Sales Growth Tysabri Important Success
Market Information Marketable Securities Including Strategic Investments
Marketable Securities Investments Marketed Products
Merger Minority Interest
Mondo Mpm
Mullens Arrangements Multiplier Individual Incentive Target Annual Base Salary
Near-term Success Depends Market Acceptance Successful Launch Product Near-term Success Depends Market Acceptance Successful Sales Growth
Neurimmune Neurobiology
Neurology New Accounting Standards
Non-gaap Financial Measures Non-marketable Securities
Non-qualified Deferred Compensation Non-qualified Deferred Compensation Table
Noncontrolling Interest Not Achieve Desired Return Significant Investment Manufacturing Facility
Not Successfully Execute Growth Initiatives Through Acquisition Partnering Not Successfully Execute Strategy Growth Through Acquisition Partnering
Notes Payable Fumedica Notes Summary Compensation Table
Ocrelizumab Humanized Anti-cd20 Antibody Off-balance Sheet Arrangements
Oncology Operating Activities
Operating Costs Expenses Operating Results Subject Significant Fluctuations
Options Exercised Stock Vested Options Exercised Stock Vested Table
Other Other Income Expense Net
Other International Other Matters
Other Matters Voted Meeting Other Net
Other Regulations Other Research Development Programs
Other Revenue Other Revenue Programs
Other Revenues Other Sources Revenue
Other-than-temporary Impairments Outcome Current Evaluation Potential Acquisition Party Uncertain Process
Outlook Overview
Part Part Other Information
Patents Other Proprietary Rights Pdl
Pending Future Product Liability Claims Adversely Affect Business Pension Plan
Performance-based Restricted Stock Units Performance-vested Restricted Stock Units
Perquisites Personal Benefits Phase Studies Tysabri
Phase Studies Tysabri Crohns Disease Picketts Arrangements
Policy Pre-approval Audit Non-audit Services Portfolio Marketable Securities Significant Subject Market Interest Credit
Post-termination Compensation Benefits Potential Payments Termination Change Control
Preferred Stock Principal Licensed Products
Principles Consolidation Pro-forma Disclosure
Problems Manufacturing Inventory Planning Result Inability Deliver Products Proceeds Marketable Securities Excluding Strategic Investments
Product Pipeline Highlights Product Revenues
Product Sales Products Infringe Intellectual Property Rights Others Incur Damages
Products Longer Sell Property Equipment
Property Plant Equipment Provisions Discounts Allowances
Pursuant 906 Sarbanes-oxley Act 2002 Ratification Selection Independent Registered Public Accounting Firm
Recent Election Directors Nominated Activist Shareholder Possibility Additional Recently Incurred Substantial Indebtedness Adversely Affect Business Limit
Recently Issued Accounting Standards Reclassification
Reclassifications Recognition Measurement Other-than-temporary Impairment
Recombinant Alpha Interferon Recombinant Beta Interferon
Recombinant Hepatitis Antigens Regulation Outside
Regulation Pertaining Sales Marketing Product Pricing Regulation Pharmaceuticals
Rely Key Personnel Rely Large Extent Parties Manufacturing Products
Rely Parties Provide Services Connection Manufacture Products Some Remaining Reserve Balance
Report Independent Registered Public Accounting Firm Represents Location Royal Sonesta Hotel
Research Development Research Development Costs
Research Development Expenses Research Triangle Park North Carolina
Reserves Discounts Allowances Restricted Stock Awards
Restructurings Retiree Medical Plan
Retirement Plans Returns
Revenue Recognition Accounts Receivable Revenues
Revenues Unconsolidated Joint Business Revolving Credit Facility
Rituxan Rituxan Anti-cd20 Antibodies
Rituxan Oncology Rituxan Other Immunology Indications
Rituxan Rituximab Rituxan Zevalin
Rituxan Zevalin Anti-cd20 Antibodies Rituxan Zevalin B-cell Nhls
Rituxan- B-cell Nhls Royalties
Royalty Revenue Royalty Revenues
Royalty Revenues Contribute Overall Profitability Not Within Control Safety Issues Tysabri Significantly Affect Growth
Sale Assets Product Line Sales Depend Payment Reimbursement Party Payors Reduction Rate
Sales Marketing Distribution Sales Marketing Product Pricing
Sales Operations Subject Risks Doing Business Internationally San Diego Oceanside California
Schedule Valuation Qualifying Accounts Reserves 2005 2004 2003 Schering
Securities Lending Securities Registered Pursuant Act
Segment Information Selling General Administrative
Selling General Administrative Expenses Senior Notes
Sentinel Study Several Aspects Corporate Governance Collaboration Agreements Discourage Party
Severance Other Costs Restructuring Plan Severance Other Restructuring Costs
Share Repurchase Program Share Repurchase Programs
Share-based Compensation Share-based Compensation Expense
Share-based Compensation Plans Share-based Payments
Shares Present Hold Meeting Shares Voted Not Vote
Signatures Significant Event
Significant Events Soliciting Proxy What Costs Proxies
Some Activities Subject Risks Federal State Laws Prohibiting Stock Options
Stock Performance Graph Stock Repurchase Programs
Stockholder Communications Board Stockholder Proposals
Stockholder Rights Plan Strategic Investments
Strategic Plan Subject Market Risk
Subject Risks Related Products Manufacture Submission Matters Vote Security Holders
Subordinated Notes Subsections 1350 Chapter Title United States Code
Subsequent Events Substantially Dependent Revenues Principal Products
Summary Contractual Maturities Available-for-sale Securities Summary Liabilities Recorded Carrying Value
Sunesis Syntonix Pharmaceuticals Inc
Table Contents Tax Rate
Tax-deductibility Compensation Tender Offer
Term Loan Facility Time-vested Restricted Stock Units
Title Class Trade Secrets Confidential Know-how
Translation Foreign Currencies Tysabri
Tysabri Natalizumab Ucb
Unable Adequately Protect Enforce Intellectual Property Rights Competitors Unable Adequately Protect Enforce Intellectual Property Rights Secure
Unable Attract Retain Qualified Personnel Key Relationships Growth Uncertainty Over Intellectual Property Biotechnology Industry Been Source
United States United States Securities Exchange
Valuation Acquired Intangible Assets In-process Research Development Expenses Valuation Inventory
Vernalis Vetter
Volatility Stock Price Vote
What Compensation Program Designed Reward What Each Element Compensation Paid
What External Market Peer Group Used Comparison Established What External Market Peer Group Used Compensation Comparisons
What Factors Considered Determining Amounts Compensation What Receive Proxy Card Voting Instruction Form
What Vote Required Approve Each Matter Votes Counted Working Capital
Zevalin Zevalin Ibritumomab Tiuxetan
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki